Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 57

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Type V hyperlipidaemia

Not recruiting

Study on Long-Term Safety and Efficacy of ARO-APOC3 for Adults with Mixed Dyslipidemia

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Phenylketonuria

Not recruiting

Study of pegvaliase injections compared to diet control in adolescents aged 12-17 with phenylketonuria (PKU)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Pegvaliase
  • Sponsor:Biomarin Pharmaceutical Inc.

Hypercholesterolaemia

Not recruiting

Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Endocrine ophthalmopathy

Not recruiting

Study on the Safety and Efficacy of Linsitinib for Patients with Active, Moderate to Severe Thyroid Eye Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Linsitinib
  • Sponsor:Sling Therapeutics Inc.

Metabolic dysfunction-associated steatohepatitis

Not recruiting

Study on the Effects of Pemafibrate and Tofogliflozin in Patients with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Pemafibrate
  • Sponsor:Kowa Research Institute Inc.

Glycogen storage disease type II

Not recruiting

Study on the Effectiveness and Safety of Avalglucosidase Alfa for Babies with Infantile-Onset Pompe Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gouty arthritis+1

Not recruiting

Study on Gout Treatment: Comparing Allopurinol, Benzbromarone, and Febuxostat in Patients with Gout in Remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Allopurinol
  • Sponsor:Sint Maartenskliniek Stichting

Type 1 diabetes mellitus

Not recruiting

Study on the Safety and Effectiveness of Diamyd and Colecalciferol for Adolescents and Adults with Recently Diagnosed Type 1 Diabetes

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Colecalciferol
  • Sponsor:Diamyd Medical AB

Glycogen storage disease type II

Not recruiting

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Fabry's disease

Not recruiting

Study on the Safety and Tolerability of ST-920 Gene Therapy for Patients with Fabry Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Isaralgagene Civaparvovec
  • Sponsor:Sangamo Therapeutics Inc.

Pituitary-dependent Cushing's syndrome

Not recruiting

Study of Lu AG13909 in Adults with Cushing's Disease to Evaluate Safety and Effectiveness

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AG13909
  • Sponsor:H. Lundbeck A/S

Endocrine ophthalmopathy

Not recruiting

Study on Batoclimab for Patients with Thyroid Eye Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.